Data collection and follow-up
ADVERSE EVENTS
The clinical and laboratory findings of the patients were assessed at baseline and 3 and 12 months. Assessment of general health status, medication use, and the occurrence of adverse events were performed at every visit. Laboratory measurements were performed at every visit, including DSA, serum creatinine, complete blood count, routine chemistry tests, electrolytes, and urinalysis. The presence of DSA was assessed using LABScreen Single Antigen Class I/Class II (One Lambda, Canoga Park, CA, USA). CD19 levels were measured at baseline and 3 months. The date of the last follow-up was August 2021.